78 studies found for:    "Monoclonal gammopathy of undetermined significance"
Show Display Options
Rank Status Study
1 Completed Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
Conditions: Smoldering Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention:
2 Completed A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Biological: Siltuximab
3 Suspended Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
Conditions: Neuropathy;   Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
Intervention: Drug: Lenalidomide
4 Active, not recruiting Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Smoldering Myeloma
Intervention: Genetic: Genetic study of DNA copies
5 Completed Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy
Conditions: Monoclonal Gammopathy;   Monoclonal Gammopathy of Undetermined Signification;   Myeloma
Intervention: Other: blood and bone marrow samples
6 Recruiting Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies
Conditions: Monoclonal Gammopathy of Unknown Significance;   Smoldering Multiple Myeloma
Intervention: Procedure: Blood Collection
7 Recruiting Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic-Myeloproliferative Diseases;   Hematological Malignancies;   B-cell Malignancy, Low-grade;   Myelodysplastic Syndrome With Low-grade Lesions;   IgG Monoclonal Gammopathy of Uncertain Significance;   Smoldering Multiple Myeloma;   Waldenstrom Macroglobulinemia
Intervention:
8 Completed
Has Results
Imaging in MGUS, SMM and MM
Conditions: Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Interventions: Drug: 18-NaF PET;   Other: DCE-MRI;   Drug: 18-FDG PET/CT
9 Completed
Has Results
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Smoldering Multiple Myeloma
Interventions: Drug: celecoxib;   Drug: placebo;   Other: laboratory biomarker analysis
10 Recruiting Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Smoldering Multiple Myeloma
Intervention: Behavioral: Relaxation Response Resiliency Program (3RP)
11 Completed S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
Conditions: Multiple Myeloma;   Smoldering Myeloma;   Waldenstrom's Macroglobulinemia;   Monoclonal Gammopathy of Undetermined Significance;   Amyloidosis
Intervention: Other: biologic sample preservation procedure
12 Enrolling by invitation B-Cell Hematologic Malignancy Vaccination Registry
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Waldenstrom Macroglobulinemia;   Lymphocytosis;   Lymphoma, Non-Hodgkin;   B-Cell Chronic Lymphocytic Leukemia;   Hematological Malignancies
Intervention:
13 Terminated
Has Results
Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
Condition: Precancerous Condition
Intervention: Biological: Rituximab
14 Active, not recruiting S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
Conditions: Multiple Myeloma;   Plasma Cell Myeloma;   Precancerous Condition
Interventions: Genetic: cytogenetic analysis;   Genetic: microarray analysis;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
15 Active, not recruiting Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Promyelocytic Leukemia (M3);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cytomegalovirus Infection;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Isolated Plasmacytoma of Bone;   Monoclonal Gammopathy of Undetermined Significance;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Multiple Myeloma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Biological: tetanus-CMV fusion peptide vaccine;   Other: laboratory biomarker analysis
16 Withdrawn Imaging Studies and the Development of Multiple Myeloma
Conditions: Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention: Drug: Fluciclatide
17 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking
18 Terminated
Has Results
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Smoldering Multiple Myeloma;   Chronic Lymphocytic Leukemia
Intervention: Dietary Supplement: Omega 3 Fatty Acid
19 Completed Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Undifferentiated Leukemia;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Gastrointestinal Stromal Tumor;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Meningeal Chronic Myelogenous Leukemia;   Monoclonal Gammopathy of Undetermined Significance;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: imatinib mesylate;   Other: pharmacological study
20 Completed RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
Condition: Polyneuropathy
Intervention: Drug: Rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years